Answers are grounded in this paper and cite their sources.
Lipid nanoparticles (LNPs) are the leading clinical platform for mRNA delivery, yet their capacity to trigger macrophage-driven inflammatory responses remains a fundamental barrier to therapeutic safety and efficacy. Here, we introduce a design principle in which a tailor-made nitric oxide (NO) inhibitory motif is embedded directly into the ionizable lipid, creating a single molecular scaffold that simultaneously delivers mRNA and suppresses macrophage inflammation. Screening of a focused acyl-guanidine library in LPS-induced peritoneal macrophages identified G9 as a potent NO inhibitor and reprogrammed macrophage polarization from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype. Conjugation of the G9 headgroup to a lipid tail yielded G9-1, an NO-inhibitory ionizable lipid that retains anti-inflammatory activity and preferentially delivers mRNA to pulmonary vascular endothelial cells and alveolar macrophages in vivo. In a murine model of acute lung injury (ALI), G9-1 LNPs loaded with IL-10 mRNA reduce pulmonary immune cell infiltration, suppress inflammatory cytokine production, and attenuate systemic inflammation. These results establish NO inhibition as an actionable molecular design principle for intrinsically anti-inflammatory LNPs and position G9-1 as a dual-function ionizable lipid for safer and more effective mRNA therapeutics.
No takes yet. Share an insight, caveat, or question.
Jian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: